The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 03, 2025

Filed:

Jun. 03, 2024
Applicant:

Miltenyi Biotec B.v. & Co. KG, Bergisch Gladbach, DE;

Inventors:

Michael Lutteropp, Bergisch Gladbach, DE;

Anne Richter, Bergisch Gladbach, DE;

Andrew Kaiser, Bergisch Gladbach, DE;

Mario Assenmacher, Bergisch Gladbach, DE;

Stefan Miltenyi, Bergisch Gladbach, DE;

Assignee:

Miltenyi Biotec B.V. & Co. Kg, Bergisch Gladbach, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 35/12 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 35/12 (2013.01); A61K 38/1774 (2013.01); A61K 39/0005 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4221 (2025.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01);
Abstract

This disclosure provides a system for preventing or reducing side effects in a patent undergoing immunotherapy to remove diseased cells that express a target antigen: for example, by CAR T cell therapy. Side effects can ensue from concurrent depletion of hematopoietic cells bearing the same target antigen. A population of engineered hematopoietic cells is prepared by obtaining healthy hematopoietic cells from the patient or a third party donor, and using them to produce engineered hematopoietic cells. The engineered cells either do not express the target antigen, express it at a lower density, or express it in a modified form. The engineered hematopoietic cells are formulated for administration to the patient, whereupon they reconstitute hematopoietic cell function, thereby preventing or reducing the side effects.


Find Patent Forward Citations

Loading…